Patents by Inventor Farman Ullah
Farman Ullah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220213057Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.Type: ApplicationFiled: January 7, 2022Publication date: July 7, 2022Inventors: Marc LABELLE, Ulrich KESSLER, Valentino CATTORI, Cyril COOK, Ramkrishna Reddy VAKITI, Kevin R. D. JOHNSON, Matinder KAUR, Jean-d'Amour K. TWIBANIRE, Farman ULLAH
-
Patent number: 11306068Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.Type: GrantFiled: June 3, 2020Date of Patent: April 19, 2022Assignee: Inthera Bioscience AGInventors: Marc Labelle, Ulrich Kessler, Valentino Cattori, Cyril Cook, Ramkrishna Reddy Vakiti, Kevin R. D. Johnson, Matinder Kaur, Jean-d'amour K. Twibanire, Farman Ullah
-
Publication number: 20200308139Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.Type: ApplicationFiled: June 3, 2020Publication date: October 1, 2020Inventors: Marc LABELLE, Ulrich KESSLER, Valentino CATTORI, Cyril COOK, Ramkrishna Reddy VAKITI, Kevin R. D. JOHNSON, Matinder KAUR, Jean-d'Amour K. TWIBANIRE, Farman ULLAH
-
Patent number: 10710975Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.Type: GrantFiled: December 17, 2018Date of Patent: July 14, 2020Assignee: Inthera Bioscience AGInventors: Marc Labelle, Ulrich Kessler, Valentino Cattori, Cyril Cook, Ramkrishna Reddy Vakiti, Kevin R. D. Johnson, Matinder Kaur, Jean-d'Amour K. Twibanire, Farman Ullah
-
Publication number: 20190185449Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.Type: ApplicationFiled: December 17, 2018Publication date: June 20, 2019Inventors: Marc LABELLE, Ulrich KESSLER, Valentino CATTORI, Cyril COOK, Ramkrishna Reddy VAKITI, Kevin R. D. JOHNSON, Matinder KAUR, Jean-d'Amour K. TWIBANIRE, Farman ULLAH
-
Patent number: 10221139Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: GrantFiled: February 17, 2017Date of Patent: March 5, 2019Assignee: GILEAD SCIENCES, INC.Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Patent number: 10189787Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: GrantFiled: August 28, 2014Date of Patent: January 29, 2019Assignee: Gilead Sciences, Inc.Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Publication number: 20170320827Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: ApplicationFiled: February 17, 2017Publication date: November 9, 2017Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Patent number: 9802941Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.Type: GrantFiled: August 26, 2015Date of Patent: October 31, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
-
Patent number: 9650339Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: GrantFiled: February 26, 2014Date of Patent: May 16, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Patent number: 9611220Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: GrantFiled: August 28, 2014Date of Patent: April 4, 2017Assignee: Gilead Sciences, Inc.Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Patent number: 9611219Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: GrantFiled: October 1, 2013Date of Patent: April 4, 2017Assignee: Gilead Sciences, Inc.Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Publication number: 20160237037Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: ApplicationFiled: February 26, 2014Publication date: August 18, 2016Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20160102096Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.Type: ApplicationFiled: August 26, 2015Publication date: April 14, 2016Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
-
Patent number: 9221801Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: GrantFiled: August 28, 2014Date of Patent: December 29, 2015Assignee: Epitherapeutics APSInventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20150203453Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: ApplicationFiled: October 1, 2013Publication date: July 23, 2015Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
-
Publication number: 20140371214Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
-
Publication number: 20140371195Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
